Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactococcus lactis-based synbiotic
- Development stage
- Preclinical
- Lead developer
- The University of Hong Kong
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactococcus lactis-based synbiotic is a proprietary therapeutic synbiotic formulation consisting of specific *Lactococcus lactis* strains and synergistic microbial metabolites. Developed by researchers at the University of Hong Kong, the bacterial strains were isolated from the feces of healthy human donors and recipient mice in a human microbiota-associated model. The synbiotic is designed to target metabolic dysfunction-associated steatotic liver disease (MASLD). In preclinical studies, oral administration of the synbiotic demonstrated significant preventive efficacy by restoring gut barrier integrity, reducing body weight gain, lowering serum transaminases (ALT and AST), and decreasing hepatic cholesterol and triglycerides.
Beyond the preview
Go deeper on Lactococcus lactis-based synbiotic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactococcus lactis-based synbiotic.